Elevance Health stock (US2855211023): investors weigh new Medicare contracts and value-based care push

Elevance Health has secured new Medicare Advantage contracts and continues to expand its value-based care and Carelon platform, while the stock trades in a consolidating range. What matters now for US healthcare investors following the latest developments?

Elevance Health stock remains in focus for US healthcare investors as the insurer expands its Medicare Advantage footprint and deepens its shift toward value-based care and services under the Carelon brand, following several recent Medicare contract awards and program updates reported in spring 2026, according to Centers for Medicare & Medicaid Services as of 04/25/2026 and company disclosures summarized by industry media in May 2026, according to Modern Healthcare as of 05/06/2026.

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elevance Health Inc.
• Sector/industry: Health insurance, managed care, health services
• Headquarters/country: Indianapolis, United States
• Core markets: US commercial, Medicaid and Medicare health plans
• Key revenue drivers: Premiums from health plans and Carelon health services
• Home exchange/listing venue: New York Stock Exchange (ticker: ELV)
• Trading currency: US dollar (USD)

Elevance Health: core business model

Elevance Health is one of the largest US health insurers and managed care groups, serving commercial, Medicaid and Medicare members with a mix of fully insured and self-funded plans, according to the company’s latest annual report published in February 2025, as cited by Elevance Health as of 02/14/2025.

The group historically operated under the Anthem brand before rebranding to Elevance Health to reflect a broader focus on whole-health solutions and analytics-driven care, according to Elevance Health as of 06/28/2022. While traditional insurance remains the largest revenue source, management has emphasized growth in health services, pharmacy benefit management and behavioral health through its Carelon segment, according to Elevance Health as of 02/14/2025.

Elevance operates Blue Cross and Blue Shield branded plans in multiple US states under license agreements, giving the company strong regional positions in key commercial and Medicaid markets, according to Blue Cross Blue Shield Association as of 01/10/2025. This network allows Elevance to negotiate with providers at scale and roll out value-based care contracts aimed at improving outcomes and managing medical cost trends.

For US investors, the stock is often viewed alongside other major managed care names such as UnitedHealth, CVS Health’s Aetna unit and Cigna, with sector performance closely tied to US healthcare policy, Medicare reimbursement trends and utilization patterns, as noted by Reuters as of 03/20/2025.

Main revenue and product drivers for Elevance Health

According to the company’s full-year 2024 results published in January 2025, Elevance Health reported double-digit growth in total operating revenue for 2024 compared with 2023, driven by membership growth in Medicaid and Medicare Advantage as well as expansion of its Carelon services business, according to Elevance Health as of 01/24/2025.

The Commercial & Specialty Business segment generates premiums from employer-sponsored plans and individual policies, with revenue influenced by membership levels, pricing, medical cost trends and the mix of risk-based versus administrative services only contracts, according to Elevance Health as of 01/24/2025. In this segment, employers increasingly seek value-based arrangements that link payments to quality and outcomes, which can benefit Elevance if it manages utilization effectively.

The Government Business segment, including Medicaid, Medicare Advantage and Medicare Supplement plans, has been a key growth driver as US demographics age and state Medicaid programs transition enrollees into managed care, according to KFF as of 11/15/2024. Recent contracts and renewals in Medicaid and Medicare Advantage markets underpin Elevance’s revenue visibility, although redeterminations in Medicaid eligibility and changes in federal reimbursement formulas can introduce volatility.

Carelon, Elevance’s health services platform, brings together pharmacy benefit management, behavioral health, complex care management and data analytics. The company has highlighted Carelon as a strategic growth vector with higher-margin fee-based revenue and cross-selling opportunities to Elevance’s insurance base and third-party clients, according to Elevance Health as of 01/24/2025.

For US investors, the balance between premium growth, medical loss ratios and the contribution from services like Carelon is central to evaluating Elevance’s earnings profile, especially as utilization patterns normalize after pandemic-related distortions, as discussed by Barron’s as of 04/02/2025.

Conclusion

Elevance Health remains a central player in US managed care, combining large-scale insurance operations with a growing services arm under the Carelon brand and recently expanded Medicare Advantage and Medicaid contracts. For US investors, the stock’s prospects are closely linked to how effectively the company navigates utilization trends, federal reimbursement decisions and competition in government programs while expanding fee-based services. The balance between growth in higher-acuity lines of business, medical cost management and capital allocation will likely remain key topics in upcoming earnings and regulatory updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.